Shanghai Yunying Biomedical Technology

Shanghai Yunying Biomedical Technology is a clinical-stage biotechnology company specializing in the development of next-generation immune cell therapies, particularly CAR-T and TCR-T treatments for solid tumors. The company leverages its proprietary technology platforms to address the challenges of the tumor microenvironment, aiming to improve the infiltration and persistence of engineered T cells. Its lead pipeline candidate, YY-101, is a GPC3-targeted CAR-T therapy currently in clinical development for hepatocellular carcinoma. Additionally, the company is advancing programs targeting Claudin 18.2 and other validated tumor antigens. Yunying Biomedical is supported by prominent venture capital firms and maintains research and manufacturing facilities in Shanghai.